Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.


PURPOSE Gemtuzumab ozogamicin (Mylotarg; Wyeth Laboratories, Philadelphia, PA) consists of a semisynthetic derivative of calicheamicin, a cytotoxic antibiotic linked to a recombinant monoclonal antibody directed against the CD33 antigen present on leukemic myeloblasts in most patients with acute myeloid leukemia (AML). In this study, we review the… (More)

6 Figures and Tables


  • Blog articles referencing this paper

  • Presentations referencing similar topics